Etavopivat

Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in advancing novel therapeutics from discovery and translational research through global clinical development, regulatory interactions and commercialization planning. "We are delighted to welcome Cameron to AN2 Therapeutics," said Eric Easom, Co-Founder, President and Chief Executive Officer of AN2 Therapeutics. "Cameron's extensive experience building and leading clinical organizations, advancing innovative therapies through development, and engaging with regulators, investigators and patients will be invaluable as we continue to advance our pipeline. His scientific rigor, patient-centric mindset and proven leadership across both emerging biotechnology companies and large pharmaceutical organizations make him an outstanding addition to our executive team.” Easom continued, “I would also like to thank Dr. George H. Talbot, Co-Founder and Senior Scientific Advisor of AN2 Therapeutics, for his leadership of our clinical programs during the last two years and his enormous contributions from day one of AN2. We are grateful for his continued commitment to the Company during the transition and as a strategic advisor going forward." Most recently, Dr. Trenor served as Chief Medical Officer of Cellarity, where he led the establishment of its medical organization through its transition to a clinical-stage biotechnology company. As Chief Medical Officer, he oversaw development of Cellarity's lead program, including the company's first IND submission and initiation of a global first-in-human clinical study. Prior to Cellarity, Dr. Trenor served as Executive Medical Director at Forma Therapeutics, which was acquired by Novo Nordisk, where he led global clinical development activities for etavopivat across multiple indications and supported the program's advancement from early clinical development into Phase 3. Earlier in his career, Dr. Trenor led clinical and translational programs in hematology and rare diseases at Novartis Institutes for BioMedical Research. He remains a practicing pediatric hematologist-oncologist at Boston Children's Hospital and has authored approximately 60 peer-reviewed research publications. Dr. Trenor received a B.S. in Biology from Tufts University, an M.D. from the University of Tennessee College of Medicine and a Master of Medical Sciences degree in Clinical Investigation from Harvard Medical School. He completed his residency and fellowship training through Boston Children's Hospital, Boston Medical Center and Dana-Farber Cancer Institute and is board-certified in Pediatric Hematology-Oncology. About AN2 Therapeutics AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical oncology candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the Company’s planned initiation of three Phase 2 trials in 2026 and declaration of two preclinical candidates and the potential impact of new personnel on the outcome of the Company’s programs. These statements are based on AN2’s current estimates, expectations, plans, objectives, and intentions, are not guarantees of future performance, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: AN2’s ability to implement its plans for its internal boron chemistry platform and pipeline programs; timely enrollment of patients in AN2’s clinical trials and investigator-initiated clinical trials; AN2’s ability to procure sufficient supply of its product candidates for its clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary, or expected results; the ability of particular preclinical models in non-human primates to predict safety and efficacy in humans; significant adverse events, toxicities, or other undesirable side effects associated with AN2’s product candidates; the significant uncertainty associated with AN2’s product candidates ever receiving any regulatory approvals; AN2’s ability to obtain, maintain, or protect intellectual property rights related to its current and future product candidates; implementation of AN2’s strategic plans for its business and product candidates; the sufficiency of AN2’s capital resources and need for additional capital to achieve its goals; global macroeconomic conditions and global conflicts and other risks, including those described under the heading “Risk Factors” in AN2’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the U.S. Securities and Exchange Commission (SEC). These filings, when made, are available on the investor relations section of AN2’s website at and on the SEC’s website at . Forward-looking statements contained in this press release are made as of this date, and AN2 undertakes no duty to update such information except as required under applicable law. Contacts COMPANY CONTACT: Lucy O. Day Chief Financial Officer l.day@an2therapeutics.com INVESTOR AND MEDIA CONTACT: Anne Bowdidge ir@an2therapeutics.com